[Management of mucinous tumor of appendix]

K A Shemyatovsky1, R Kh Azimov1, P S Glushkov1

  • 1Central Clinical Hospital of Russian Academy of Sciences, Moscow, Russia.

Khirurgiia
|October 8, 2020
PubMed

Insights

Low-grade mucinous tumors (MT) of the appendix are rare and can lead to peritoneal pseudomyxoma. Current classification and treatment approaches are lacking, often delaying diagnosis and worsening patient prognosis.

Area of Science:

  • Oncology
  • Gastroenterology
  • Pathology

Background:

  • Low-grade mucinous tumors (MT) of the appendix are uncommon malignancies.
  • A significant complication is peritoneal pseudomyxoma due to mucin deposition.
  • Current diagnostic and therapeutic strategies for appendiceal MT are inadequate.

Purpose of the Study:

  • To highlight the challenges in diagnosing and managing low-grade mucinous tumors of the appendix.
  • To underscore the need for improved clinical-pathomorphological classification and treatment protocols.
  • To emphasize the impact of delayed diagnosis on patient outcomes.

Main Methods:

  • Review of existing literature on appendiceal mucinous tumors.
  • Analysis of clinical presentations and diagnostic challenges.
  • Discussion of treatment complexities and prognostic factors.

Main Results:

  • Appendiceal MT are frequently discovered incidentally after appendectomy for presumed acute appendicitis.
  • Preoperative diagnosis of MT is often not possible, complicating early management.
  • Peritoneal pseudomyxoma significantly worsens the prognosis for patients with MT.

Conclusions:

  • There is a critical need for standardized clinical-pathomorphological classifications for appendiceal MT.
  • Development of unified treatment guidelines is essential for improving patient outcomes.
  • Early suspicion and diagnosis are crucial for mitigating the severe consequences of MT, such as peritoneal pseudomyxoma.

Related Concept Videos

Appendicitis-II: Diagnostic Studies and Management01:29

Appendicitis-II: Diagnostic Studies and Management

Diagnosing and managing appendicitis requires a structured and comprehensive approach that spans from initial assessment to postoperative care. Here is an overview of the process:
Diagnosing Appendicitis
It requires a multifaceted approach, starting with a detailed physical examination to pinpoint the location and nature of the pain and identify any associated symptoms. Laboratory tests play a crucial role. A complete Blood Count (CBC) typically reveals leukocytosis (an increased number of...
308
Appendicitis-I: Introduction01:22

Appendicitis-I: Introduction

The appendix, a small, narrow, blind tube extending from the inferior part of the cecum, is widely regarded as a vestigial organ, having lost much of its original function through evolution. Despite its diminished role, the appendix can become inflamed, a condition known as appendicitis.
Etiology: Appendicitis can arise from various causes, primarily rooted in the obstruction of the appendix lumen. Factors contributing to this obstruction include fecal accumulation, lymphoid hyperplasia and, in...
1.5K
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
333
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
200
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
332